Sign In
Buy HALO
$69.82
+3.54 (+5.34%)
At Close: Jun 03, 2026
Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes"
01:46pm, Tuesday, 09'th Jul 2024
Halozyme Therapeutics (HALO) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
01:48pm, Monday, 08'th Jul 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
3 Highly Rated Biotech Stocks for Your July Buy List
06:20am, Friday, 05'th Jul 2024
The healthcare sector continues to be a hotbed of innovation, with biotechnology leading the charge. From groundbreaking gene therapies to next-generation cancer treatments, biotech companies are push
How Small Biotech Halozyme, With A 41% Run, Is Getting Under Your Skin
08:00am, Wednesday, 03'rd Jul 2024
Small biotech company Halozyme is behind some of the biggest names in medicine, including Johnson & Johnson's Darzalex and Roche's Tecentriq.
3 Breakout Biotech Stocks on Track to Double by 2032
10:02am, Monday, 01'st Jul 2024
With the technology sector taking over in 2024, now is a great time to consider the best breakout biotech stocks to buy. Investing in these companies can be risky yet extremely rewarding, with careful
OCREVUS® subcutaneous (SC) injection offers a new 10-minute administration with comparable efficacy and safety to intravenous (IV) infusion Provides an additional treatment option without the need fo
VYVGART® Hytrulo is the first and only neonatal Fc receptor (FcRn) blocker that is delivered as a subcutaneous injection, approved to treat chronic inflammatory demyelinating polyneuropathy (CIDP)
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
10:46am, Monday, 17'th Jun 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The 3 Best Healthcare Stocks to Buy in June 2024
04:00pm, Saturday, 15'th Jun 2024
The healthcare sector will be one area of secular growth over the next decade. Several demand drivers will benefit the best healthcare stocks to buy across the entire value chain.
Halozyme Therapeutics (HALO) is a Top-Ranked Momentum Stock: Should You Buy?
10:51am, Tuesday, 11'th Jun 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
02:34pm, Friday, 07'th Jun 2024
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
02:34pm, Friday, 07'th Jun 2024
The top five biotech stocks today have several commonalities. Among them are strong ratings.
Halozyme (HALO) Raises 2024 Financial Guidance, Stock Up 13%
10:00am, Friday, 07'th Jun 2024
Halozyme (HALO) gains 13% as it raises its full-year 2024 financial guidance and updates its five-year financial outlook based on the new ENHANZE patent grant in Europe.
Halozyme Therapeutics (HALO) Up 8.7% Since Last Earnings Report: Can It Continue?
12:36pm, Thursday, 06'th Jun 2024
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?
Halozyme's (HALO) ENHANZE Product Gets New Patent Grant in EU
10:35am, Thursday, 06'th Jun 2024
Halozyme (HALO) is set to benefit from the new patent grant in the EU, ensuring the protection of its ENHANZE rHuPH20 product in several EU countries until 2029.
